4.3 Review

In Vivo Flow Cytometry: A Horizon of Opportunities

期刊

CYTOMETRY PART A
卷 79A, 期 10, 页码 737-745

出版社

WILEY
DOI: 10.1002/cyto.a.21143

关键词

flow cytometry; spectral imaging; photoacoustic and photothermal methods; fluorescence; Raman spectroscopy; blood and lymph flows; circulating tumor cells, bacteria, and multicolor nanoparticles; theranostics

资金

  1. National Institutes of Health [R01CA131164, R01EB009230, R01EB000873, R21CA139373]
  2. National Science Foundation [DBI-0852737]
  3. Department of Defense [W88XWH-10-2-0130, W81XWH-10-BCRP-CA, W81XWHAQ711-1-0129]
  4. RFBR [10-07-00526-a]
  5. Photonics4life [224014]
  6. RF Ministry of Education and Science [1.4.09, 2.1.1/4989, 2.2.1.1/2950]
  7. RF Government [02.740.11.0484, 02.740.11.0770, 02.740.11.0879]
  8. FiDiPro, TEKES, Finland [3081/31/2010, x 32.20.40.2.4/11]
  9. Direct For Biological Sciences
  10. Div Of Biological Infrastructure [0852737] Funding Source: National Science Foundation

向作者/读者索取更多资源

Flow cytometry (FCM) has been a fundamental tool of biological discovery for many years. Invasive extraction of cells from a living organism, however, may lead to changes in cell properties and prevents studying cells in their native environment. These problems can be overcome by use of in vivo FCM, which provides detection and imaging of circulating normal and abnormal cells directly in blood or lymph flow. The goal of this review is to provide a brief history, features, and challenges of this new generation of FCM methods and instruments. Spectrum of possibilities of in vivo FCM in biological science (e.g., cell metabolism, immune function, or apoptosis) and medical fields (e.g., cancer, infection, and cardiovascular disorder) including integrated photoacoustic-photothermal theranostics of circulating abnormal cells are discussed with focus on recent advances of this new platform. (C) 2011 International Society for Advancement of Cytometry

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据